FITZGERALDS ENDOCRINE EXAM QUESTIONS WITH
GUARANTEED ACCURATE ANSWERS |VERIFIED
1.In caring for a patient with DM, microalbuminuria measurement should be obtained:
A. annually if urine protein is present
B. periodically in relationship to glycemia control
C. yearly
D. with each office visit related to DM - ANSWER C
2.The mechanism of action of sulfonylureas is as:
A. an antagonist of insulin receptor site activity
B. a product that enhances insulin release
C. a facilitator of renal glucose excretion
D. an agent that can reduce hepatic glucose production - ANSWER B
3.When caring for a patient with DM, HTN, and persistent proteinuria, the NP prioritizes the
choice of antiHTN and prescribes:
A. furosemide
B. methyldopa
C. fosinopril
D. nifedipnie - ANSWER C
4.Clinical presentation of T1DM usually includes all of the following except:
,A. report of recent unintended weight gain
B. ketosis
C. thirst
D. polyphagia - ANSWER A
5.Which of the following should be periodically monitored with the use of a biguanide?
A. creatinine kinase CK
B. alkaline phosphatase ALP
C. alanine aminiotransferase ALT
D. creatinine Cr - ANSWER D
6.Which of the following should be periodically monitored with the use of a thiazolidinedione?
A. CK
B. ALP
C. ALT
D. Cr - ANSWER C
7.All of the following are risks for lactic acidosis in individuals taking metformin except:
A. presence of chronic renal insufficiency
B. acute dehydration
C. radiographic contrast dye use
D. history of allergic reaction to sulfonamides - ANSWER D
,8.Secondary causes of hyperglycemia potentially include the use of all of the following
medications except:
A. high dose niacin
B. systemic corticosteroids
C. high dose thiazide diuretics
D. low dose angiotensin receptor blockers - ANSWER D
9.Which of the following characteristics applies to T1DM?
A. Significant hyperglycemia and ketoacidosis result from lack of insulin
B. This condition is commonly diagnosed on routine exam for other health problems.
C. Initial response to oral sulfonylureas is usually favorable
D. Insulin resistance is a significant part of the disease. - ANSWER A
10.Which of the following characteristics applies to T2DM?
A. Major risk factors are hereditary and obesity.
B. Pear shaped body type is commonly found.
C. Exogenous insulin is needed for control disease.
D. Physical activity enhances IR. - ANSWER A
11.You consider prescribing insulin glargine (Lantus) because of its:
A. extended duration of action
, B. rapid onset of action
C. ability to prevent diabetic end organ damage
D. ability to preserve pancreatic function - ANSWER A
12.After use, the onset of action of lispro (Humalog) occurs in:
A. less than 30 minutes
B. approx. 1 hour
C. 1-2 hours
D. 3-4 hours - ANSWER A
13.Which of the following medications should be used with caution in a person with suspected
or known sulfa allergy?
A. metformin
B. glyburide
C. rosiglitazone
D. NPH insulin - ANSWER B
14.The mechanism of action of metformin (Glucophage) is as:
A. an insulin production enhancer
B. a product virtually identical in action to sulfonylureas
C. a drug that increases insulin action in the peripheral tissues and reduces hepatic glucose
production
D. a facilitator of renal glucose excretion - ANSWER C
GUARANTEED ACCURATE ANSWERS |VERIFIED
1.In caring for a patient with DM, microalbuminuria measurement should be obtained:
A. annually if urine protein is present
B. periodically in relationship to glycemia control
C. yearly
D. with each office visit related to DM - ANSWER C
2.The mechanism of action of sulfonylureas is as:
A. an antagonist of insulin receptor site activity
B. a product that enhances insulin release
C. a facilitator of renal glucose excretion
D. an agent that can reduce hepatic glucose production - ANSWER B
3.When caring for a patient with DM, HTN, and persistent proteinuria, the NP prioritizes the
choice of antiHTN and prescribes:
A. furosemide
B. methyldopa
C. fosinopril
D. nifedipnie - ANSWER C
4.Clinical presentation of T1DM usually includes all of the following except:
,A. report of recent unintended weight gain
B. ketosis
C. thirst
D. polyphagia - ANSWER A
5.Which of the following should be periodically monitored with the use of a biguanide?
A. creatinine kinase CK
B. alkaline phosphatase ALP
C. alanine aminiotransferase ALT
D. creatinine Cr - ANSWER D
6.Which of the following should be periodically monitored with the use of a thiazolidinedione?
A. CK
B. ALP
C. ALT
D. Cr - ANSWER C
7.All of the following are risks for lactic acidosis in individuals taking metformin except:
A. presence of chronic renal insufficiency
B. acute dehydration
C. radiographic contrast dye use
D. history of allergic reaction to sulfonamides - ANSWER D
,8.Secondary causes of hyperglycemia potentially include the use of all of the following
medications except:
A. high dose niacin
B. systemic corticosteroids
C. high dose thiazide diuretics
D. low dose angiotensin receptor blockers - ANSWER D
9.Which of the following characteristics applies to T1DM?
A. Significant hyperglycemia and ketoacidosis result from lack of insulin
B. This condition is commonly diagnosed on routine exam for other health problems.
C. Initial response to oral sulfonylureas is usually favorable
D. Insulin resistance is a significant part of the disease. - ANSWER A
10.Which of the following characteristics applies to T2DM?
A. Major risk factors are hereditary and obesity.
B. Pear shaped body type is commonly found.
C. Exogenous insulin is needed for control disease.
D. Physical activity enhances IR. - ANSWER A
11.You consider prescribing insulin glargine (Lantus) because of its:
A. extended duration of action
, B. rapid onset of action
C. ability to prevent diabetic end organ damage
D. ability to preserve pancreatic function - ANSWER A
12.After use, the onset of action of lispro (Humalog) occurs in:
A. less than 30 minutes
B. approx. 1 hour
C. 1-2 hours
D. 3-4 hours - ANSWER A
13.Which of the following medications should be used with caution in a person with suspected
or known sulfa allergy?
A. metformin
B. glyburide
C. rosiglitazone
D. NPH insulin - ANSWER B
14.The mechanism of action of metformin (Glucophage) is as:
A. an insulin production enhancer
B. a product virtually identical in action to sulfonylureas
C. a drug that increases insulin action in the peripheral tissues and reduces hepatic glucose
production
D. a facilitator of renal glucose excretion - ANSWER C
